✦ LIBER ✦

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

✍ Scribed by Robert Haddad; Marshall Posner

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 32 KB
Volume: 97
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.11194

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of induction chemotherapy

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

✍ Dong M. Shin; Bonnie S. Glisson; Fadlo R. Khuri; Scott M. Lippman; Lawrence Gins 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract ## BACKGROUND This Phase II trial was conducted to determine the response rate, particularly of the primary sites, tolerability, and toxicity of induction chemotherapy of paclitaxel, ifosfamide, and carboplatin for patients with previously untreated locally advanced squamous cell carci

Phase II study of paclitaxel, ifosfamide

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma

✍ Dong M. Shin; Fadlo R. Khuri; Bonnie S. Glisson; Lawrence Ginsberg; Vali M. Papa 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

A Phase II study of paclitaxel and ifosf

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

✍ Christopher J. Sweeney; Stephen D. Williams; David E. Finch; Richard Bihrle; Ric 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## BACKGROUND. Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated. METHODS. Ifosfamide 1.0 gm/m 2 on Days 1-4 and paclitaxel 135 mg/m 2 by 24-hour infusion on Day 4 were ad

Ifosfamide, cisplatin, and 13-Cis retino

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck : A Phase I–II study

✍ Francesco Recchia; Angelo Lalli; Marco Lombardo; Sandro De Filippis; Gaetano Sag 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 3 views

Paclitaxel, cisplatin, and 5-fluorouraci

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi

Pilot study of intraoperative chemothera

Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck

✍ Ozlem E. Tulunay; Ileana I. Enamorado; Omer Kucuk; Lance K. Heilbrun; Jose E. Ot 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## Background. Intraoperative manipulation of the tumor during cancer surgery has long been recognized as a source of metastasis and contamination of the surgical wound during tumor removal. We explored the use of intraoperative chemotherapy to minimize the risk of tumor cell implantat